Skip to main content
Proceedings of the American Thoracic Society logoLink to Proceedings of the American Thoracic Society
. 2010 Feb 15;7(1):71–76. doi: 10.1513/pats.200908-089JS

The Role of the Ubiquitin Proteasome Pathway in Keratin Intermediate Filament Protein Degradation

Micah R Rogel 1, Ariel Jaitovich 1, Karen M Ridge 1
PMCID: PMC3137152  PMID: 20160151

Abstract

Lung injury, whether caused by hypoxic or mechanical stresses, elicits a variety of responses at the cellular level. Alveolar epithelial cells respond and adapt to such injurious stimuli by reorganizing the cellular cytoskeleton, mainly accomplished through modification of the intermediate filament (IF) network. The structural and mechanical integrity in epithelial cells is maintained through this adaptive reorganization response. Keratin, the predominant IF expressed in epithelial cells, displays highly dynamic properties in response to injury, sometimes in the form of degradation of the keratin IF network. Post-translational modification, such as phosphorylation, targets keratin proteins for degradation in these circumstances. As with other structural and regulatory proteins, turnover of keratin is regulated by the ubiquitin (Ub)-proteasome pathway. The degradation process begins with activation of Ub by the Ub-activating enzyme (E1), followed by the exchange of Ub to the Ub-conjugating enzyme (E2). E2 shuttles the Ub molecule to the substrate-specific Ub ligase (E3), which then delivers the Ub to the substrate protein, thereby targeting it for degradation. In some cases of injury and IF-related disease, aggresomes form in epithelial cells. The mechanisms that regulate aggresome formation are currently unknown, although proteasome overload may play a role. Therefore, a more complete understanding of keratin degradation—causes, mechanisms, and consequences—will allow for a greater understanding of epithelial cell biology and lung pathology alike.

Keywords: intermediate filaments, ubiquitin proteasome pathway, degradation


Proteins are continually being hydrolyzed to their constituent amino acids by highly selective proteolytic systems. Interestingly, proteins are degraded at widely differing rates that can vary from minutes for some regulatory enzymes, to days or weeks for proteins such as actin and myosin in skeletal muscle, or months for hemoglobin in the red cell. This process of continually destroying cellular proteins has important homeostatic functions, such as regulating cell cycle, signal transduction, differentiation, and response to stress. In all tissues, the majority of intracellular proteins are degraded by the ubiquitin (Ub)-proteasome pathway (UPP). If the UPP fails to degrade intracellular proteins, such as during stress, the accumulation of misfolded protein may overload the proteasome, potentially leading to pathogenesis.

PROTEIN DEGRADATION VIA THE UPP

The degradation of a protein via the UPP involves two successive steps: (1) tagging of the substrate by covalent attachment of multiple Ub molecules, and (2) degradation of the tagged protein into small peptides by the 26S proteasome complex with release of free and reusable Ub (Figure 1). The E1 (Ub-activating enzyme) and E2s (Ub-carrier or conjugating proteins) prepare Ub for conjugation, but the key enzyme in the process is the E3 (Ub-protein ligase), because it recognizes a specific protein substrate and catalyzes the transfer of activated Ub to the target protein. The 2004 Nobel Prize in Chemistry was awarded to Aaron Ciechanover, Avram Hershko, and Irwin Rose (http://nobelprize.org/chemistry/laureates/2004/) for the discovery of the UPP.

Figure 1.

Figure 1.

Protein degradation via the ubiquitin proteasome pathway.

Ub and the Ligases

Ub is composed of 76 amino acids. A key glycine residue within the C-terminus is required for its conjugation to other Ub molecules and target substrates; it also contains internal lysine residues that are required for the formation of polyubiquitin chains. The initial step in conjugation of Ub onto proteins is activation of Ub at its C-terminus by the Ub-activating enzyme E1. This abundant 110-kD enzyme uses ATP to generate a Ub thioester, a highly reactive form of Ub (1, 2). Once activated, the Ub that is bound to E1 via the thioester linkage is transferred to a sulfhydryl group of one of the Ub carrier proteins or an E2. The E2s are small proteins that share a conserved 16-kD core containing the cysteine that forms a thioester linkage with the activated Ub.

The more than 1,000 E3 ligases in cells confer high specificity to the UPP. E3 ligases function either as single proteins or in complexes to link E2s to proteins either directly or via another protein (2). Essentially, E3s act as scaffolds and often catalyze the transfer of the activated Ub from E2s to a lysine in the target protein and subsequently to lysines that are present in Ub, yielding a substrate-anchored chain of Ub molecules. The two best-studied classes of E3s that may play predominate roles in keratin intermediate filament (IF) protein degradation are the HECT (homologous to E6-AP carboxy-terminus) domain proteins and the RING finger proteins. HECT-domain proteins are large monomeric E3s possessing a homolog C-terminal domain, which accepts the activated Ub from the E2. This exchange occurs via the formation of a thioester linkage with Ub, catalyzing Ub transfer to the substrate. Unlike HECT-domain–containing E3s, E3s with RING finger domains are either monomeric enzymes or multi-subunit complexes and do not form thioester bonds with Ub. Rather, they typically serve as scaffolds that bring the substrate and the E2 into close proximity and may assist in formation of a Ub chain (3). Monomeric RING finger E3s include the oncoprotein Mdm2 (4), a physiologic regulator of p53 stability in normal cells, and c-Cbl (5), which catalyzes ubiquitination of certain cell surface receptors.

The 26S Proteasome

Found both in the cytosol and nucleus of cells, the 26S proteasome catalyzes the rapid degradation of ubiquitinated proteins (6). This enormous complex is composed of a central barrel-shaped 20S core particle with a 19S regulatory particle at either or both of its ends (7). The proteolytic capacity of the 26S proteasome lies within the 20S core. It is composed of four stacked, hollow rings, each containing seven distinct but related subunits (8). The two outer α rings are identical, as are the two inner β rings. Three subunits of the β rings contain the proteolytically active sites, positioned on the interior face of the cylinder. The outer α subunits of the 20S particle surround a narrow, central, and gated pore through which substrates enter and products exit (8). The physical architecture of the 19S particle selects, prepares, and translocates substrates into the 20S core for degradation. The outer lid of the 19S particle contains subunits that bind polyubiquitin chains, as well as two deubiquitinating enzymes (also called isopeptidases) that disassemble Ub chains, allowing for reuse of Ub in the degradation of other proteins (9). After deubiquitination, target proteins are unfolded and processed through the 20S particle in an ATP-dependent manner. After the substrate enters the central chamber of the 20S particle, the polypeptide is cleaved by the six proteolytic sites on the inner face of the chamber, resulting in small peptides that range from 3 to 23 residues in length (10). These peptides are then rapidly digested into constituent amino acids by the abundant cytosolic endopeptidases and aminopeptidases and reused to synthesize new proteins or are metabolized (11).

STRUCTURE, FUNCTION, AND DEGRADATION OF IFs

IFs, microfilaments (MFs), and microtubules (MTs) are the key structural proteins that form a dynamic cytoskeleton. IFs make up a large protein family that includes 73 unique gene products, which places the genes encoding them among the 100 largest gene families in humans (12). Several features distinguish IFs from MFs and MTs, including IF structural diversity, tissue- and cell-selective expression, unique subcellular compartment distribution (lamins are found in the nucleus, whereas the remaining IFs are in the cytoplasm), and, most relevant, their involvement in more than 80 human diseases (Human Intermediate Filament Database, http://www.interfil.org/index.php) (13). Another contrast to MFs and MTs is the fact that, to this date, no inhibitors of IF assembly are known. IFs are grouped into six types (types I–VI): types I through IV are found in the cytoplasm, the type V IF proteins are found in the nucleus, and those classified as type VI are found exclusively in the lens. Type III proteins, such as vimentin, are found primarily in endothelial, hematopoietic, and mesenchymal cells. The largest group consists of type I and type II keratins found in epithelial cells. In the cells of higher organisms, several types of IFs are expressed at once; for example, both type V lamins and type III vimentin can be expressed in parallel within a single cell type. Despite the great number of genes and diverse tissue distribution, the IFs in many different cell types are morphologically similar. They have a structurally conserved central rod domain, composed of heptad repeats that are required for the coiled-coil interactions involved in the assembly of IFs (14). The rod domain is flanked by variable N- and C-terminal domains. The basic unit of all IFs is a dimer composed of two α-helical chains that are oriented in parallel and interact to form a very stable coiled-coil rod (Figure 2). Dimers associate in an antiparallel, half-staggered manner to form a larger unit, which in turn grows in length to form protofilaments. Lateral associations of protofilaments give rise to protofibrils and three to four of these protofibrils intertwine to form the stable 10-nm filament. In epithelial cells, a single type I (acidic) and type II (neutral-basic) keratin chain form heterodimers. Alveolar epithelial cells specifically express four keratin proteins: K8, K18, K7, and K19. In the lung, K8 and K18 are equally expressed, and we focus on these two proteins in this review.

Figure 2.

Figure 2.

Structure of intermediate filaments.

Although the classical concept states that IFs are static structures merely serving a structural function within cells, a great deal of recent data support the idea that IFs are actually dynamic and important for many cellular functions. This paradigm shift occurred in part because studies using fluorescent recovery after bleaching and microinjection of fluorescently tagged IF proteins showed that a dynamic equilibrium exists between IF subunits (particles and squiggles) and IF filaments. In terms of IF function, it has been accepted for many years that IFs provide mechanical support to cells. We are now aware of many more IF functions, including their involvement in cellular migration, mitosis, and signal transduction. These functions are likely made possible by the dynamic nature of IFs, with the disassembly and reassembly processes dependent on reorganization. For example, IF assembly occurs sequentially from particles to squiggles to filaments in spreading cells (15, 16), and IFs disassemble during cell division. IF proteins can move rapidly in either a retrograde or anterograde direction along microtubule tracks, suggesting that cells possess a mechanism for regulating IF distribution to locally tune cellular properties, such as shape and adhesion. Vimentin IFs may organize to form a “cage” or shield at the cell periphery, presumably to enable cells (e.g., lymphocytes) to resist mechanical stresses, or they may rapidly reassemble to a perinuclear location during chemotaxis. Likewise, epithelial cells undergo a process to enable migration into injured areas of the alveolar epithelium. These changes are made possible through site-specific phosphorylation. Accumulating data suggest that epithelial cells' keratin IFs can undergo rapid disassembly and degradation in response to insults such as mechanical stress, shear stress, or hypoxia. These data and other data suggest that the IF cytoskeleton transmits signals from the cell surface to all regions of the cytoplasm (17). IFs within the cytoplasm can transmit extracellular signals by binding to and regulating the activity of signaling proteins, either via a receptor or adaptor mechanism. Changes in IFs, occurring either through post-translational modification, composition, or association with other proteins, can modulate these signals. This signaling function regulates a variety of cellular programs, including stress response and migration, mitosis, differentiation, and more.

During many of these normal programs, such as mitosis, IFs undergo significant and reversible disassembly. In other cases, such as during stress, IFs may undergo irreversible protein degradation. Destruction of a protein can lead to a complete, rapid, and sustained termination of the process involving the protein as well as a change in cell composition. The rapid degradation of specific proteins permits adaptation to new physiologic conditions. At times this process can be detrimental to the function of cells, and in some cases it may actually be protective. For the most part, IF protein degradation is complete, but in some cases accumulation may occur. Accumulation of partially degraded IF protein can lead to a specific pathological feature known as aggresomes.

KERATIN IFs AND AGGRESOMES

The expression of IF proteins is highly regulated during development and cell differentiation, and can be markedly altered in cells and tissues undergoing an injury response. A diversity of human diseases is associated with severe alterations of IFs (18). One common pathological feature of many IF-related diseases is the accumulation of intracytoplasmic inclusion bodies or aggresomes consisting of modified IF proteins. Examples include the neurodegenerative diseases amyotrophic lateral sclerosis, Pick disease, and Parkinson disease (19). Common to all these diseases are aggresomes made up mainly of IFs and Ub. In alcoholic hepatitis and other liver disorders aggresomes are referred to as Mallory-Denk bodies (MDBs) (20). The morphology and biochemical composition of MDBs in liver disorders is constant. MDBs are typically irregularly shaped, at times globular, and located near the nucleus. However, MDBs have also been observed at the cell periphery, associated in distinct cases with keratin IFs or desmosomes (21). These different locations were correlated to stages of MDB formation in the griseofulvin-fed mouse model; in this model, smaller, globular aggresomes reflect early formation of MDBs, whereas in later stages of formation, the MDBs become larger, perinuclear structures (22). Aggresomes are also observed in renal cell carcinoma (23), nonneoplastic pancreatic cells (24), and patients with interstitial pneumonitis (25), as well as in the cytoplasm of especially swollen alveolar epithelial cells. These cytoplasmic aggresomes are composed of intermediate-type fine fibrils, which are positive for anti-keratin antibody—predominantly K8 and variable amounts of K18 assembled in a nonfilamentous manner (26). In addition to keratin, nonkeratin components, such as Ub, have also been identified as constituents of aggresomes (19). These facts suggest that they represent a kind of pathological keratinization of injured epithelial cells, including those found in the alveolar epithelium of the lung.

Aggresomes consist of filamentous aggregates of misfolded proteins and other protein-based components to various degrees and combinations. The major constituents include: cytokeratins (often post-translationally modified); chaperones, such as heat shock proteins (hsp 70, hsp 90); degradation machinery, including p62 and Ub; and a small group of other proteins (27, 28). Although aggresomes were first described in hepatocytes in 1911, it was not until 1979 that keratin IFs were identified as the major constituent (29). In epithelial cells, the main constituents are keratins 8 and 18 (K8 and K18), typically in a hyperphosphorylated state (3032). In fact, hyperphosphorylated keratin IFs are plentiful in aggresomes of other cells, possibly even initiating their formation (31, 33). Signaling pathways, such as src, AKT, p38, and ERK, likely mediate this process (3335). For example, p38 has directly been shown to phosphorylate K8 at Ser73 (34, 36). A study using diethyl-1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate (DDC)-primed mice showed that MAPK p38, Ub, and p62 colocalized with K8 in cytokeratin aggresomes (34). Inhibition of p38 phosphorylation by SB202190 prevented cytokeratin aggresome formation. Thus, hyperphosphorylation of K8 by p38 kinase seems to be a key step in the process of aggresome formation. These studies support the concept that keratin IF phosphorylation appears to act as a degradation marker for UPP, and that there is a connection between polyubiquitinated aggregates and proteasome overload. Keratin aggregation and aggresome formation has also been observed in human liver cells when the proteasome is inhibited by oxidative stress induced with ethanol treatment (37). The proteasome inhibitor, PS-341, induces formation of aggresomes, again characterized by colocalization of K8 and Ub in a perinuclear location (38). Another study using an in vitro kidney model showed that either overexpression or inhibition of proteasome activity allows formation of misfolded protein (cystic fibrosis transmembrane conductance regulator) aggregates to occur (39).

Although the formation of aggresomes arises by multiple mechanisms, their morphology and biochemical composition remain fairly constant across tissue type and pathology. The location of these bodies within the cell, on the other hand, appears to be less consistent. For example, although aggresomes are usually found near the nucleus, they may also be present throughout the cytoplasm or near the cell periphery associated with desmosomes (21, 40, 41). In general, the aggregates appear to sequester into one or more foci throughout the cell. Morphologically, the basic filamentous structure can vary from a completely random arrangement to filaments oriented parallel to one another. The IFs contained within Mallory bodies (aggresomes) was described by Franke and colleagues in 1979 as “randomly oriented, branched filaments” with diameter 14 to 20 nm, much thicker than the 10-nm width of normal IFs (29). Also unlike normal keratin IFs, these proteins were covered by a thick coat of threads projecting out from the filament surface. Other characteristics of aggregates include poor solubility, abnormal localization, and nonnative secondary structure.

KERATIN IFs AND THE UPP IN ALVEOLAR EPITHELIAL CELLS

The keratin IF network in alveolar epithelial cells have different measured responses depending on the external stimuli. For example, alveolar epithelial cells exposed to stretch at 20% deformation show no change in keratin IF assembly state, suggesting that stretch does not activate signal transduction pathways involved in their disassembly and degradation (30). In contrast, shear stress appears to promote the disassembly and reorganization of the keratin IF network in alveolar epithelial cells in a time-dependent manner (37, 38). Brief periods of shear stress cause the keratin IF network to reorganize from thin, long, and relatively straight filaments into thick, wavy, “tonofibrils” (keratin IF bundles). In conjunction with this reorganization, keratin protein solubility decreases and the exchange rate of keratin subunits significantly increases. Importantly, the stiffness of these cells also increases by approximately 40%, with local stiffness values decreasing according to distance from the nucleus. The increase in stiffness enables cells to withstand injurious mechanical forces (e.g., mechanical ventilation), whereas the keratin network distribution would protect the nucleus and enhance cellular plasticity at the cell periphery. The rate and extent of keratin IF disassembly and degradation exhibits a dependence on the degree of shear stress (30); increased levels of shear stress accelerate the rate of disassembly and reorganization of the keratin IF network. The disassembly and degradation of keratin proteins is regulated by post-translational modifications, mainly phosphorylation and ubiquitination (24, 26). The initial step in this process appears to be “tagging” the keratin protein for degradation via phosphorylation. Phosphorylation is known to occur within the head and tail domains, which are responsible for most of the structural heterogeneity and presumed tissue-specific functions of IF (42). In the case of keratin 8, a number of in vivo phosphorylation sites have been mapped, and these play essential roles in regulating filament assembly and disassembly in vivo (42). IF can be phosphorylated by a variety of kinases, including protein kinase C, which is activated by mechanical forces. As such, shear stress, but not stretch, activates PKC δ and phosphorylates K8 on serine 73, which then initiates the disassembly and degradation of keratin IF in alveolar epithelial cells (30, 32).

The keratin IF network is known to colocalize with Ub in response to stress (Figure 3) (32). In our study, continuous exposure to shear stress resulted in the formation of perinuclear aggresomes containing both keratin and Ub. The aggresomes were present in approximately 30% of the cells. Colocalization of Ub cross-reactive protein with the keratin IF network has been observed in A549 cells as well (43). These structures may form when the proteasome capacity is exceeded (39) or inhibited, resulting in the subsequent accumulation of ubiquitinated proteins within aggresomes. Jaitovich and colleagues demonstrated that soluble keratin protein is degraded at an accelerated rate compared with insoluble, filamentous keratin protein (32). These results demonstrated that insoluble, filamentous keratin protein is not efficiently degraded via the UPP compared with soluble, nonfilamentous keratin. This could be due the restrictive pore size of the 19S proteasome complex with requires nano-sized proteins to be “fed” through the proteasome. Proteasome inhibition by MG132 (carbobenzoxy-l-leucyl-l-leucyl-l-leucinal) prevents degradation of keratin IF network in response to mechanical strain (32). Other studies similarly report an accumulation of phosphorylated K8 and K18 when the proteasome is inhibited (44).

Figure 3.

Figure 3.

The keratin intermediate filament network is known to colocalize with ubiquitin in response to stress.

Different E2 enzymes, such as UbcH5b, UbcH5c, and Ubc6, are required for the shear stress- and/or hypoxia-mediated Ub-proteasome degradation of the keratin proteins (32). Ubc5 family members and Ubc3 participate in the degradation of keratin IF proteins under mechanical stress (32), whereas Ubc6 mediates the keratin degradation under hypoxia (45). Members of the UbcH5 family are highly homologous. UbcH5b and c are 97% identical at the amino acid level (with a difference of only four amino acids), and it is likely that they have similar biologic activities (46). The various E2s associated with keratin IF protein degradation may reflect the different cellular functions associated with Ub E2s. Although the precise biological role of many of the Ub E2s is not well defined in mammalian cells, there is accumulating evidence that E2s have unique functions. For example, Ubc3 is required for the G1-S transition, Ubc2 is central to DNA repair, and Ubc 4/5 is required for viability in Saccharomyces cerevisiae (1). In the case of hypoxic stress, overexpression of Ubc-6–dominant negatives prevent keratin degradation. Ubc-6 is an integral membrane protein that has been previously described to be localized to the endoplasmic reticulum and to the nuclear membrane, and to mediate the turnover of the short-lived transcriptional regulators and other endoplasmic reticulum–associated protein (47). These functions may be dependent on the specificity for the individual E3s. The E3 protein associated with keratin IF protein degradation has not yet been identified.

CONCLUSIONS

It is unclear whether accumulation of proteins such as keratin IFs plays a correlative, or causative, role in lung injury or epithelial-related disease. Formation of aggregates consisting of modified IF, Ub, p62, chaperones, and other proteins most probably occurs in response to cellular malfunction or stress, but the question then is whether their presence is protective, harmful, or neutral to injured or diseased cells. On the one hand, sequestration of abnormal proteins should promote cellular homeostasis by preventing their interference with important cellular processes. Cells containing aggresomes are typically viable (48), and aggresome (Mallory body) formation is even reversible and accompanied by the reappearance of the keratin cytoskeleton in mouse hepatocytes (41). On the other hand, these aggregates could be toxic to cells by interfering with the mechanical functions of a cell or by hindering the function of degradation machinery. In addition, aggregation of ubiquitinated proteins has been shown to impair the function of the UPP, resulting in cell death (49). Finally, the withdrawal of cytoplasmic components, such as the IF cytoskeleton, has tremendous implications for epithelial cellular function and, at the larger scale, tissue integrity. The most striking evidence for this fact can be seen in blistering diseases, such as epidermolysis bullosa simplex (EBS), caused by point mutations of keratins, wherein the mechanical integrity of cells is critically compromised (18, 50). Identification of the components involved in the Ub-proteasome–mediated degradation of keratin IFs will be essential in understanding how these key structural proteins may contribute to the physiologic functions of alveolar epithelial cells. Whether or not these processes are coregulated has great implications for understanding the formation and accumulation of IF aggresomes.

Supported by grants from the National Institutes of Health PO1-HL71643 and RO1-HL079190 (K.M.R.).

Conflict of Interest Statement: None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

References

  • 1.Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001;70:503–533. [DOI] [PubMed] [Google Scholar]
  • 2.Ciechanover A, Schwartz AL. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 1998;95:2727–2730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 1999;96:11364–11369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 1999;18:22–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Lee PS, Wang Y, Dominguez MG, Yeung YG, Murphy MA, Bowtell DD, Stanley ER. The Cbl protooncoprotein stimulates csf-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation. EMBO J 1999;18:3616–3628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003;426:895–899. [DOI] [PubMed] [Google Scholar]
  • 7.Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, Huber R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997;386:463–471. [DOI] [PubMed] [Google Scholar]
  • 8.Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science 1995;268:533–539. [DOI] [PubMed] [Google Scholar]
  • 9.Glickman MH, Rubin DM, Coux O, Wefes I, Pfeifer G, Cjeka Z, Baumeister W, Fried VA, Finley D. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the cop9-signalosome and eif3. Cell 1998;94:615–623. [DOI] [PubMed] [Google Scholar]
  • 10.Kisselev AF, Akopian TN, Woo KM, Goldberg AL. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem 1999;274:3363–3371. [DOI] [PubMed] [Google Scholar]
  • 11.Tamura N, Lottspeich F, Baumeister W, Tamura T. The role of tricorn protease and its aminopeptidase-interacting factors in cellular protein degradation. Cell 1998;95:637–648. [DOI] [PubMed] [Google Scholar]
  • 12.Omary MB. “IF-pathies”: A broad spectrum of intermediate filament-associated diseases. J Clin Invest 2009;119:1756–1762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Fuchs E, Cleveland DW. A structural scaffolding of intermediate filaments in health and disease. Science 1998;279:514–519. [DOI] [PubMed] [Google Scholar]
  • 14.Herrmann H, Strelkov SV, Feja B, Rogers KR, Brettel M, Lustig A, Haner M, Parry DA, Steinert PM, Burkhard P, et al. The intermediate filament protein consensus motif of helix 2b: its atomic structure and contribution to assembly. J Mol Biol 2000;298:817–832. [DOI] [PubMed] [Google Scholar]
  • 15.Prahlad V, Yoon M, Moir RD, Vale RD, Goldman RD. Rapid movements of vimentin on microtubule tracks: kinesin-dependent assembly of intermediate filament networks. J Cell Biol 1998;143:159–170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Windoffer R, Leube RE. Detection of cytokeratin dynamics by time-lapse fluorescence microscopy in living cells. J Cell Sci 1999;112:4521–4534. [DOI] [PubMed] [Google Scholar]
  • 17.Herrmann H, Bar H, Kreplak L, Strelkov SV, Aebi U. Intermediate filaments: from cell architecture to nanomechanics. Nat Rev Mol Cell Biol 2007;8:562–573. [DOI] [PubMed] [Google Scholar]
  • 18.Omary MB, Coulombe PA, McLean WH. Intermediate filament proteins and their associated diseases. N Engl J Med 2004;351:2087–2100. [DOI] [PubMed] [Google Scholar]
  • 19.Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, Landon M, Mayer RJ. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J Pathol 1988;155:9–15. [DOI] [PubMed] [Google Scholar]
  • 20.Ku NO, Michie SA, Soetikno RM, Resurreccion EZ, Broome RL, Oshima RG, Omary MB. Susceptibility to hepatotoxicity in transgenic mice that express a dominant-negative human keratin 18 mutant. J Clin Invest 1996;98:1034–1046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Denk H, Stumptner C, Zatloukal K. Mallory bodies revisited. J Hepatol 2000;32:689–702. [DOI] [PubMed] [Google Scholar]
  • 22.Denk H, Franke WW, Eckerstorfer R, Schmid E, Kerjaschki D. Formation and involution of Mallory bodies (“Alcoholic hyalin”) in murine and human liver revealed by immunofluorescence microscopy with antibodies to prekeratin. Proc Natl Acad Sci USA 1979;76:4112–4116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Jagirdar J, Irie T, French SW, Patil J, Schwarz R, Paronetto F. Globular Mallory-like bodies in renal cell carcinoma: report of a case and review of cytoplasmic eosinophilic globules. Hum Pathol 1985;16:949–952. [DOI] [PubMed] [Google Scholar]
  • 24.Pasquinelli G, Preda P, Martinelli GN, Galassi A, Santini D, Venza E. Filamentous inclusions in nonneoplastic and neoplastic pancreas: an ultrastructural and immunogold labeling study. Ultrastruct Pathol 1995;19:495–500. [DOI] [PubMed] [Google Scholar]
  • 25.Nonomura A, Kono N, Ohta G. Pulmonary cytoplasmic hyalin resembling Mallory's alcoholic hyalin in the liver. Acta Pathol Jpn 1986;36:869–878. [DOI] [PubMed] [Google Scholar]
  • 26.Hazan R, Denk H, Franke WW, Lackinger E, Schiller DL. Change of cytokeratin organization during development of Mallory bodies as revealed by a monoclonal antibody. Lab Invest 1986;54:543–553. [PubMed] [Google Scholar]
  • 27.Riley NE, Li J, McPhaul LW, Bardag-Gorce F, Lue YH, French SW. Heat shock proteins are present in Mallory bodies (cytokeratin aggresomes) in human liver biopsy specimens. Exp Mol Pathol 2003;74:168–172. [DOI] [PubMed] [Google Scholar]
  • 28.Riley NE, Bardag-Gorce F, Montgomery RO, Li J, Lungo W, Lue YH, French SW. Microtubules are required for cytokeratin aggresome (Mallory body) formation in hepatocytes: an in vitro study. Exp Mol Pathol 2003;74:173–179. [DOI] [PubMed] [Google Scholar]
  • 29.Franke WW, Denk H, Schmid E, Osborn M, Weber K. Ultrastructural, biochemical, and immunologic characterization of Mallory bodies in livers of griseofulvin-treated mice. Fimbriated rods of filaments containing prekeratin-like polypeptides. Lab Invest 1979;40:207–220. [PubMed] [Google Scholar]
  • 30.Ridge KM, Linz L, Flitney FW, Kuczmarski ER, Chou YH, Omary MB, Sznajder JI, Goldman RD. Keratin 8 phosphorylation by protein kinase C delta regulates shear stress-mediated disassembly of keratin intermediate filaments in alveolar epithelial cells. J Biol Chem 2005;280:30400–30405. [DOI] [PubMed] [Google Scholar]
  • 31.Cadrin M, Anderson NM, Aasheim LH, Kawahara H, Franks DJ, French SW. Modifications in cytokeratin and actin in cultured liver cells derived from griseofulvin-fed mice. Lab Invest 1995;72:453–460. [PubMed] [Google Scholar]
  • 32.Jaitovich A, Mehta S, Na N, Ciechanover A, Goldman RD, Ridge KM. Ubiquitin-proteasome-mediated degradation of keratin intermediate filaments in mechanically stimulated a549 cells. J Biol Chem 2008;283:25348–25355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Yuan QX, Nagao Y, Gaal K, Hu B, French SW. Mechanisms of Mallory body formation induced by okadaic acid in drug-primed mice. Exp Mol Pathol 1998;65:87–103. [DOI] [PubMed] [Google Scholar]
  • 34.Nan L, Dedes J, French BA, Bardag-Gorce F, Li J, Wu Y, French SW. Mallory body (cytokeratin aggresomes) formation is prevented in vitro by p38 inhibitor. Exp Mol Pathol 2006;80:228–240. [DOI] [PubMed] [Google Scholar]
  • 35.Wu Y, Nan L, Bardag-Gorce F, Li J, French BA, Wilson LT, Dedes J, French SW. The role of laminin-integrin signaling in triggering MB formation. An in vivo and in vitro study. Exp Mol Pathol 2005;79:1–8. [DOI] [PubMed] [Google Scholar]
  • 36.Ku NO, Azhar S, Omary MB. Keratin 8 phosphorylation by p38 kinase regulates cellular keratin filament reorganization: modulation by a keratin 1-like disease causing mutation. J Biol Chem 2002;277:10775–10782. [DOI] [PubMed] [Google Scholar]
  • 37.Bardag-Gorce F, French BA, Nan L, Song H, Nguyen SK, Yong H, Dede J, French SW. Cyp2e1 induced by ethanol causes oxidative stress, proteasome inhibition and cytokeratin aggresome (Mallory body-like) formation. Exp Mol Pathol 2006;81:191–201. [DOI] [PubMed] [Google Scholar]
  • 38.Bardag-Gorce F, Riley NE, Nan L, Montgomery RO, Li J, French BA, Lue YH, French SW. The proteasome inhibitor, ps-341, causes cytokeratin aggresome formation. Exp Mol Pathol 2004;76:9–16. [DOI] [PubMed] [Google Scholar]
  • 39.Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998;143:1883–1898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.French SW. Present understanding of the development of Mallory's body. Arch Pathol Lab Med 1983;107:445–450. [PubMed] [Google Scholar]
  • 41.Denk H, Franke WW. Rearrangement of the hepatocyte cytoskeleton after toxic damage: involution, dispersal and peripheral accumulation of Mallory body material after drug withdrawal. Eur J Cell Biol 1981;23:241–249. [PubMed] [Google Scholar]
  • 42.Omary MB, Ku O-N, Price D, editors. Keratin modifications and solubility properties in epithelial cells and in vitro. New York: Plenum Press; 1998. [PubMed]
  • 43.Loeb KR, Haas AL. Conjugates of ubiquitin cross-reactive protein distribute in a cytoskeletal pattern. Mol Cell Biol 1994;14:8408–8419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Ku NO, Omary MB. Keratins turn over by ubiquitination in a phosphorylation-modulated fashion. J Cell Biol 2000;149:547–552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Ni N CN, Litvan J, Ridge KM. Mitochondrial reactive oxygen species are required for hypoxia-induced degradation of keratin intermediate filaments. FASEB J [Epub ahead of print on 2009 Nov 6 as doi:10.1096/fj.08-128967]. [DOI] [PMC free article] [PubMed]
  • 46.Zwickl P, Voges D, Baumeister W. The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 1999;354:1501–1511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Biederer T, Volkwein C, Sommer T. Degradation of subunits of the Sec61p complex, an integral component of the ER membrane, by the ubiquitin-proteasome pathway. EMBO J 1996;15:2069–2076. [PMC free article] [PubMed] [Google Scholar]
  • 48.Zatloukal K, Spurej G, Rainer I, Lackinger E, Denk H. Fate of Mallory body-containing hepatocytes: disappearance of Mallory bodies and restoration of the hepatocytic intermediate filament cytoskeleton after drug withdrawal in the griseofulvin-treated mouse. Hepatology 1990;11:652–661. [DOI] [PubMed] [Google Scholar]
  • 49.Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001;292:1552–1555. [DOI] [PubMed] [Google Scholar]
  • 50.Gu LH, Coulombe PA. Keratin function in skin epithelia: a broadening palette with surprising shades. Curr Opin Cell Biol 2007;19:13–23. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the American Thoracic Society are provided here courtesy of American Thoracic Society

RESOURCES